Valerie Gouon-Evans PhD, PharmD
Associate Professor, Gastroenterology
Member, Genome Science Institute
670 Albany St | (617) 414-2971valerige@bu.edu
Sections
Gastroenterology
Centers
Center for Regenerative Medicine
Evans Center for Interdisciplinary Biomedical Research
Biography
Valerie Gouon-Evans, PharmD, PhD is Associate Professor of Medicine in the Section of Gastroenterology at the Chobanian and Avedisian School of Medicine, Director of the Program of Boston University Liver Biologists (BULB), and Associate Director of the Molecular & Translational Medicine (MTM) PhD Program of the Department of Medicine.
After completing her graduate studies in Paris, Dr. Gouon-Evans joined Dr. Pollard's Lab as a postdoctoral fellow where she studied mammary gland development and breast cancer. She then began her career as an Instructor of Gene and Cell Medicine at the Icahn School of Medicine at Mount Sinai School of Medicine in New York in the laboratory of Dr. Gordon Keller, where she pioneered protocols to efficiently generate hepatocyte-like cells from pluripotent stem cells. She quickly rose up the ranks and was promoted to Assistant Professor before arriving at Boston University. As a PharmD PhD lab leader for 16 years, Dr. Gouon-Evans has overseen the creation of a research program to advance understanding of liver development and establishing therapeutic strategies to alleviate liver disease using an induced pluripotent stem cell platform and mouse models. Recently, Dr. Gouon-Evans lab also pioneered an innovative technology to deliver regenerative factors to the liver to treat various liver diseases, by using mRNA complexed to lipid nanoparticles, which is a validated platform with the widely used mRNA-based COVID-19 vaccines.
Other Positions
Education
Biology, PhD, University of Paris Vii
Pharmacy, PharmD, Université Paris 5 René Descartes
Biology, MS, University of Paris Vii
Biochemistry, BS, Pierre and Marie Curie University (Paris VI)
Publications
Smith AR, Rizvi F, Everton E, Adeagbo A, Wu S, Tam Y, Muramatsu H, Pardi N, Weissman D, Gouon-Evans V. Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy to treat murine liver diseases. bioRxiv. 2024 Jan 11. PMID: 38260488.
Published on 11/28/2023Rizvi F, Lee YR, Diaz-Aragon R, Bawa PS, So J, Florentino RM, Wu S, Sarjoo A, Truong E, Smith AR, Wang F, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A, Shin D, Gouon-Evans V. VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. Cell Stem Cell. 2023 Dec 07; 30(12):1640-1657.e8. PMID: 38029740.
Published on 4/18/2023Everton E, Del Rio-Moreno M, Villacorta-Martin C, Singh Bawa P, Lindstrom-Vautrin J, Muramatsu H, Rizvi F, Smith AR, Tam Y, Pardi N, Kineman R, Waxman DJ, Gouon-Evans V. Growth Hormone Accelerates Recovery From Acetaminophen-Induced Murine Liver Injury. bioRxiv. 2023 Apr 18. PMID: 37131727.
Published on 4/18/2023Rizvi F, Lee YR, Diaz-Aragon R, So J, Florentino RM, Smith AR, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A, Shin D, Gouon-Evans V. VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. bioRxiv. 2023 Apr 18. PMID: 37131823.
Published on 4/17/2023Gouon-Evans V, Fiorotto R. Fibroblasts to hepatocytes: A nonstop flight into cell therapy for liver diseases? Hepatology. 2023 May 01; 77(5):1469-1471. PMID: 35957526.
Published on 2/10/2023Kim M, Rizvi F, Shin D, Gouon-Evans V. Update on Hepatobiliary Plasticity. Semin Liver Dis. 2023 Feb; 43(1):13-23. PMID: 36764306.
Published on 4/7/2022Smith AR, Gouon-Evans V. c-Maf: The magic wand that turns on LSEC fate. Cell Stem Cell. 2022 Apr 07; 29(4):491-493. PMID: 35395181.
Published on 10/5/2021Everton E, Rizvi F, Smith AR, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA. Bio Protoc. 2021 Oct 05; 11(19):e4184. PMID: 34722830.
Published on 5/10/2021Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Author Correction: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021 May 10; 12(1):2825. PMID: 33972545.
Published on 1/27/2021Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021 01 27; 12(1):613. PMID: 33504774.